Search

Displaying results 831 - 840 of 10000 in total
  1. Drug

    Manidipine

    go.drugbank.com/drugs/DB09238
    ApprovedInvestigationalWithdrawn

    Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.

    Products: IPERTEN 20 MG TABLET, 28 ADET, คาดิพลอท 20
  2. Drug

    Pimozide

    go.drugbank.com/drugs/DB01100
    Approved

    A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknow...

    Products: NOROFREN 2 MG TABLET, 20 ADET, NOROFREN 2 MG TABLET, 500 ADET
  3. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...

    Products: TAFINLAR 50 MG KAPSUL, 20 ADET, TAFINLAR (CAPSULES 50 MG)
  4. Drug

    Nitrazepam

    go.drugbank.com/drugs/DB01595
    Approved

    A benzodiazepine derivative used as an anticonvulsant and hypnotic.

    Products: IPNOZEM TABLET, 20 ADET, NITRADOS TABLET 5 mg
  5. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.

    Products: Nubain 10 mg/ml Injektionslösung, NALBUFINA CLORHIDRATO 10 MG/ML.
  6. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. … On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.

    Products: ROFECOXIB MK 25 MG TABLETAS, ROFECOXIB MK 12.5 MG TABLETAS
  7. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy

    Products: TYSABRI 300 MG I.V. INFUZYON ICIN KONSANTRE COZELTI ICEREN FLAKON, 1 ADET, Tysabri 150 mg SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (2 adet)
  8. Drug

    Potassium permanganate

    go.drugbank.com/drugs/DB13831
    Investigational

    Products: POTASSIO PERMANGANATO MARCO VITI
  9. Drug

    Capecitabine

    go.drugbank.com/drugs/DB01101
    ApprovedInvestigational

    Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, wh...

    Products: XELTABIN 500 MG FILM KAPLI TABLET, 20 ADET, CAPETABIN 500 MG FILM KAPLI TABLET ,1TABLET, 20 ADET
  10. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    [A193272,A193275,L12648] Avastin was subsequently approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. … [A286054] In 2004, bevacizumab (Avastin) gained FDA approval and became the first antiangiogenic agent introduced to the market, indicated in combination with chemotherapy regimens specific to the type

    Categories: Complex MixturesProducts: ZİRABEV 100 MG/4 ML İNFÜZYONLUK ÇÖZELTİ, 1 ADET, ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/4 ML